API
< Back to all clusters
[HEALTH] · Australia · 7 sources

started · updated

Amplia Therapeutics receives ethics approval for pancreatic cancer drug trial

Amplia Therapeutics has obtained ethics approval to commence its ACCENT-Mini clinical trial, testing its lead drug candidate, narmafotinib, in patients with metastatic pancreatic cancer. The trial will evaluate a daily-dosed regimen of the drug alongside standard chemotherapy to determine optimal safe and effective dosing rates.

Recruitment is set to begin across three clinical trial sites in Australia. The study builds upon previous ACCENT trial data, which reported a 36 per cent confirmed tumour response rate when combining intermittent narmafotinib doses with gemcitabine and Abraxane. This outperformed chemotherapy alone and achieved a median overall survival of 11.1 months.

Narmafotinib functions by blocking Focal Adhesion Kinase (FAK), a protein found at high levels in solid tumours. By inhibiting FAK, the drug aims to weaken the dense, fibrotic tissue that protects cancer cells, potentially enhancing the efficacy of chemotherapy.

Entities

Amplia Therapeutics · Australia · Borland Lake · Chris Burns · Dominic Duggan · Gorman project · Ontario · Patriot Resources · narmafotinib